November 2018 Volume 27 Issue S1

Section 1: Modelling the impact of a new tobacco product: review of Philip Morris International’s Population Health Impact Model as applied to the IQOS heated tobacco product

W B Max, H-Y Sung, J Lightwood, Y Wong, T Yoo

Section 2: Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims

I Popova, L K Lempert, S A Glantz

Section 3: Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products

J Elias, P M Ling

Section 4: Revolution or redux? Assessing IQOS through a precursor product

J Elias, I M Dutra, G St. Helen, P M Ling

Research letters

Section 1: Tobacco-specific nitrosamines (TSNA) in heated tobacco product IQOS

N J Leigh, M N Palmbe, A M Marino, R J O’Connor, M L Goniewicz

Section 2: Possible hepatotoxicity of IQOS

I L Chum, F Moadz, E Manthey, C Calfée, J Gots

Industry watch

Section 1: IQOS campaign in Israel

I J Rosen, S Kislev

Section 2: Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control

S A Bialous, S A Glantz

Section 3: Heated tobacco product regulation under US law and the FCT

L K Lempert, S A Glantz

Contents

Commentaries
s1 Heated tobacco products: the example of IQOS
S A Glantz

s7 Heated tobacco products: things we do and do not know
I Stupanov, A Woodward

Research papers
s9 PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes
S A Glantz

s13 Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke
P Nakovitsidch, J Liu, C M Havel, S Ibrahim, R Derakhshanadch, P Jacob III, M L Springer

s20 Assessment of industry data on pulmonary and immunosuppressive effects of IQOS
F Aloaez, L Chun, M A Manthey, C S Calfé, J Gots

s30 IQOS: examination of Philip Morris International’s claim of reduced exposure
G St. Helen, P Jacob III, N Nardone, N L Benowitz

s41 Heated tobacco products likely appeal to adolescents and young adults
K McKevey, L Popova, M Kim, B W Chaffee, M Vijayaraghavan, P Ling, B Halpern-Felsher

s48 IQOS labelling will mislead consumers
K McKevey, L Popova, M Kim, L K Lempert, B W Chaffee, M Vijayaraghavan, P Ling, B Halpern-Felsher

s55 Awareness and use of heated tobacco products among US adults, 2016–2017
A L Nyman, S R Weather, L Popova, T F Pechacek, J Huang, D L Ashley, M P Erikson

s62 Impact of modified risk tobacco product claims on beliefs of US adults and adolescents
S El-Toukhy, S A Baig, M Jeong, M J Byron, K M Rønild, N T Brewer

s70 Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland
E C Hair, M Bennett, E Sheen, J Canelles, J Briggs, Z Fenn, J C Wilton, D Vallone

s78 IQOS campaign in Israel
I J Rosen, S Kislev

s82 Modelling the impact of a new tobacco product: review of Philip Morris International’s Population Health Impact Model as applied to the IQOS heated tobacco product
W B Max, H-Y Sung, J Lightwood, Y Wong, T Yoo

s87 Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims
I Popova, L K Lempert, S A Glantz

s96 Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products
J Elias, P M Ling

s102 Revolution or redux? Assessing IQOS through a precursor product
J Elias, I M Dutra, G St. Helen, P M Ling